Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; College of Stomatology, Shanghai Jiao Tong University, Shanghai, China; National Center for Stomatology, Shanghai, China; National Clinical Research Center for Oral Diseases, Shanghai, China; Shanghai Key Laboratory of Stomatology, Shanghai, China; Shanghai Research Institute of Stomatology, Shanghai, China; Shanghai Center of Head and Neck Oncology Clinical and Translational Science, Shanghai, China; Research Unit of Oral and Maxillofacial Regenerative Medicine, Chinese Academy of Medical Sciences, Shanghai, China.
Faculty of Dentistry, University of Debrecen, Debrecen, Hungary.
J Stomatol Oral Maxillofac Surg. 2024 Oct;125(5S2):101970. doi: 10.1016/j.jormas.2024.101970. Epub 2024 Jul 19.
Head and Neck Squamous Cell Carcinoma (HNSCC) ranks as the sixth most prevalent form of cancer worldwide. MRE11 protein contains multiple domains that play a role in the initiation of DNA repair. This study aimed to elucidate the expression and prognostic significance of MRE11 in HNSCC.
The Cancer Genome Atlas (TCGA-HNSCC) dataset comprising 520 HNSCC tissues and 44 normal tissues was initially used to evaluate the association between MRE11 expression and clinicopathologic characteristics. Kaplan-Meier plot was utilized for survival analysis. MRE11-immune cell interaction was analyzed using Tumor Immune Estimation Resource (TIMER) database. Further, Insilco methods were used to explore the protein network and its association with other pathways. Quantitative reverse transcription PCR (RT-qPCR) was used to validate the MRE11 mRNA expression in oral squamous cell carcinoma (OSCC) tissues in patient samples.
MRE11 expression was upregulated in HNSCC, and the expression significantly varied across different clinical stages, pathological grades, and initial treatment outcomes. Further, high MRE11 expression is associated with poorer survival outcomes. MRE11 overexpression is also linked to the activation of the HIPPO signaling pathway, the mTOR signaling pathway, and the MYC/MYCN signaling pathway.
MRE 11 can be considered a novel prognostic biomarker for HNSCC, which can be leveraged for promising treatment outcomes. This research highlights MRE11 as a novel molecular biomarker for HNSCC and offers a new direction for its treatment, explicitly targeting MRE11 and its network for therapeutic intervention.
头颈部鳞状细胞癌（HNSCC）是全球第六大常见癌症。MRE11 蛋白包含多个结构域，在 DNA 修复的起始中发挥作用。本研究旨在阐明 MRE11 在 HNSCC 中的表达及其预后意义。
首先使用包含 520 例 HNSCC 组织和 44 例正常组织的癌症基因组图谱（TCGA-HNSCC）数据集来评估 MRE11 表达与临床病理特征之间的关系。使用 Kaplan-Meier 图进行生存分析。使用肿瘤免疫估计资源（TIMER）数据库分析 MRE11-免疫细胞相互作用。进一步，使用 Insilco 方法来探索蛋白质网络及其与其他途径的关联。使用定量逆转录 PCR（RT-qPCR）验证患者样本中口腔鳞状细胞癌（OSCC）组织中的 MRE11 mRNA 表达。
MRE11 在 HNSCC 中表达上调，其表达在不同的临床分期、病理分级和初始治疗结果中存在显著差异。此外，高 MRE11 表达与较差的生存结果相关。MRE11 过表达还与 HIPPO 信号通路、mTOR 信号通路和 MYC/MYCN 信号通路的激活有关。
MRE11 可作为 HNSCC 的一种新的预后生物标志物，有望改善治疗效果。本研究强调了 MRE11 作为 HNSCC 的一种新的分子标志物，并为其治疗提供了新的方向，明确针对 MRE11 及其网络进行治疗干预。
